A PHASE III, OPEN-LABEL, MULTICENTER,TWO-ARM, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZOLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED BRAFV600 WILD-TYPE MELANOMA

Protocol: 
AAAR4467
Phase: 
III

A PHASE III, OPEN-LABEL, MULTICENTER,TWO-ARM, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZOLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED BRAFV600 WILD-TYPE MELANOMA

Are you Eligible? (Inclusion Criteria)

-18 years of age or older
- Life expectancy of greater than or equal to three months
- Patients cannot have ocular melanoma
- No history of hypersensitivity to cobimetinib, atezolizumab,
pembrolizumab, or ipilimumab

Specialty Area(s)

Immunotherapy

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States